AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

upload.jpg

Development and Characterisation of AD-214 for the treatment of IPF

The peer reviewed journal mAbs have published a comprehensive overview of the preclinical research supporting clinical development of our first in class molecule AD-214 for Idiopathic Pulmonary Fibrosis and other fibrotic diseases. This makes our research significantly more accessible to potential partners and collaborators.

AD-214 publication in peer reviewed journal mAbs